Loading...
PDE4 inhibitor rolipram inhibits the expression of microsomal prostaglandin E synthase‐1 by a mechanism dependent on MAP kinase phosphatase‐1
Phosphodiesterase‐4 (PDE4) inhibitors have recently been introduced to the treatment of COPD and psoriatic arthritis. Microsomal prostaglandin E synthase‐1 (mPGES‐1) is an inducible enzyme synthesizing PGE (2), the most abundant prostanoid related to inflammation and inflammatory pain. mPGES‐1 is a...
Saved in:
| Published in: | Pharmacol Res Perspect |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
John Wiley and Sons Inc.
2017
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5723697/ https://ncbi.nlm.nih.gov/pubmed/29226622 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.363 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|